NOTCH1 Loss-of-function

CI-VAR-00002526Explore in graph →CIViC 601

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Head and Neck Squamous Cell Carcinoma2
NOTCH1 Loss-of-function	Bimiralisib	Predictive	B	Supports Sensitivity Response	3	submitted	EID13292 In a phase II, nonrandomized, single-arm trial (NCT03740100), 8 patients with recurrent/metastatic HNSCC harboring NOTCH1 mutations predicted to cause loss of function received bimiralisib after prior… (full text at CIViC) PMID 36124629 · Johnson et al., 2022 · Open in CIViC	civic
NOTCH1 Loss-of-function	Porcupine Inhibitor WNT974	Predictive	D	Supports Sensitivity Response	2	accepted	EID1525 In an evaluation of 96 head and neck squamous cell carcinoma (HNSCC) cell lines, 31 were responsive to LGK974 (PORCN inhibitor). Of 40 cell lines (25 responsive, 15 non-responsive) that were exome seq… (full text at CIViC) PMID 24277854 · Liu et al., 2013 ·

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.